October 9, 2018

Appili Therapeutics Appoints Seasoned Infectious Disease Global Drug Development Executive Dr. Theresa Matkovits to Its Board of Directors

October 1, 2018

Appili Therapeutics Appoints Veteran Drug Development Executive, Dr. Armand Balboni, as Its Inaugural Chief Scientific Officer

August 16, 2018

Appili Therapeutics Announces Results of 2018 Annual and Special Meeting

July 30, 2018

Appili Therapeutics Completes Phase 1 Study for ATI-1501, Its Taste-Masked Oral Metronidazole Suspension

June 21, 2018

Appili Therapeutics to Present at 2018 Atlantic Venture Forum Technology Showcase

April 18, 2018

Appili Therapeutics to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference

February 7, 2018

Appili Therapeutics Raises an Additional $4.3 Million in Oversubscribed Financing to Advance its Anti-infective Pipeline

January 26, 2018

Appili Recognized as ‘New Business of the Year’ by the Halifax Chamber of Commerce

January 9, 2018

Appili Therapeutics Licenses BioTerrorism Vaccine Rights